Microba's Recent Trading Update

Microba Life Sciences (ASX:MAP) has released a trading update ahead of its Annual General Meeting. The company highlights robust performance in its diagnostic and therapeutic segments. Key achievements include record MetaXplore sales in Australia, international expansion, and advancing therapeutic developments.

Microba's Strategic Outlook

Microba Life Sciences is making significant strides in the microbiome diagnostics and therapeutics sectors. The company reports record sales growth in Australia for its MetaXplore product and anticipates further growth with its MetaPanel product. Internationally, Microba is expanding into the UK with an early access program and increased sales staff. Therapeutically, the company is progressing its MAP 315 program towards a Phase 2 clinical trial for inflammatory bowel disease. Financially, Microba maintains a healthy cash balance while pursuing reimbursement pathways and therapeutic development in the USA. The company's strategic focus remains on expanding its market reach and advancing its clinical trials.

Executive Commentary on Growth and Strategy

October saw record MetaXplore sales in Australia, with strong momentum continuing into November. MetaPanel sales have reached a milestone of over 500 tests since its launch in March 2024, with growing clinical adoption anticipated due to upcoming study results and publications.